Early diagnosis of prostate cancer using cancer-specific the glycosylated peptide antibody
| Project/Area Number |
23592350
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
FUJIMURA Tsutomu 順天堂大学, 医学(系)研究科(研究院), 准教授 (70245778)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 悪性前立腺がん / ハプトグロビン / 糖鎖修飾ペプチド / ペプチド抗体 / がん特異的抗体 / シアル酸化 / フコシル化 / ELISA / シアル酸 / ＥＬＩＳＡ法 / PSA値 / 国際情報交流 |
|---|
| Research Abstract |
[Purpose] I found haptoglobin who received sugar chain modification cancer-specific from malignant prostate cancer patients serum. The antibody was produced to antigen glycosylated peptide from a cancer patient serum-derived haptoglobin. I aimed at the early diagnosis of prostate cancer. [Result] Antibody produced was possible to distinguish healthy control and malignant prostate cancer patients. To also distinguish between malignant prostate cancer and benign disease patients was also possible. The prototype that can be measured by ELISA was able to sufficient sensitivity is obtained.It was detectable the number ng / ml sugar chain haptoglobin in serum. I was able to produce ELISA to make up for the shortcomings of PSA levels. Furthermore, we want to raise the accuracy of the early diagnosis method by increase the number of samples.
|
Report
(4 results)
Research Products
(38 results)
-
-
-
[Journal Article] PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation.2014
Author(s)
Furuya N, Ikeda SI, Sato S, Soma S, Ezaki J, Trejo JA, Takeda-Ezaki M, Fujimura T, Arikawa-Hirasawa E, Tada N, Komatsu M, Tanaka K, Kominami E, Ueno T.
-
Journal Title
Autophagy
Volume: 10
Issue: 4
Pages: 631-41
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Integrative genomic and proteomic analysis of low-dose ionizing irradiation effects on bone marrow stromal microenvironment and on survival of pre-leukemic cells.2013
Author(s)
Tabe Y, Jin L, Hatanaka Y, Matsushita H, Kazuno S, Fujimura T, Ueno U, Sasai K, Iwabuchi K, Andreeff M, Konopleva M, MD, Miida T.
Organizer
55th American Society of Hematology Annual Meeting
Place of Presentation
New Orleans in U.S.A.
Related Report
-
[Presentation] Efficacy and mechanisms of the mTOR inhibitor AZD2014 combined with L-Asparaginase or JAK2 inhibitor TG101348 in ALL.2013
Author(s)
Tabe Y, Jin L, Iwanami H, Matsushita H, Kazuno S, Fujimura T, Ueno T, Miida T, Weinstock D, Thomas D.A, Andreeff M, Konopleva M.
Organizer
55th American Society of Hematology Annual Meeting
Place of Presentation
New Orleans in USA
Related Report
-
-
[Presentation] Molecular mechanisms of inhibition of ribosomal biogenesis and translational flux by the Selective Inhibitor of Nuclear Export (SINE) XPO1/CRM1 antagonist KPT-185 in mantle cell lymphoma.2013
Author(s)
Tabe Y, Kojima K, Jin L, Iwanami H, Matsushita H, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno U, Miida T, Andreeff M.
Organizer
55th American Society of Hematology Annual Meeting
Place of Presentation
New Orleans in USA
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
